<DOC>
	<DOCNO>NCT01277640</DOCNO>
	<brief_summary>The purpose study determine safety male genitalia expose dapivirine gel follow seven daily application .</brief_summary>
	<brief_title>Male Tolerance Study Dapivirine Gel Following Multiple Topical Penile Exposures</brief_title>
	<detailed_description />
	<criteria>At least 18 year age Screening , verify per site standard operate procedure ( SOP ) Able willing provide write informed consent screen take part study At Screening , able willing provide adequate locator information , define per site SOP Able willing communicate write spoken English HIVuninfected Screening per Algorithm Appendix II In general good health , accord clinical judgment Investigator Record ( IoR ) designee Willing abstain vaginal , oral anal intercourse ( include receptive anal intercourse ) , even condom ; masturbation , activity may cause irritation injury penis study participation Willing abstain use genitallyapplied preparation ( except use usual cleansing product genital hygiene ) study product study participation Willing abstain nonurgent surgical procedure penis/GU area duration study participation ( e.g . circumcision ) At Screening Enrollment , agree participate research study involve drug , medical device , genital product duration study participation ( followup visit complete ) Participant report follow : Known adverse reaction study product component study product ( ever ) Postexposure prophylaxis ( PEP ) HIV exposure within 6 month prior Enrollment Penile procedure ( e.g . biopsy , circumcision ) within 42 day less prior Enrollment Participation research study involve drug , medical device , genital product within 30 day less prior Enrollment Within three month prior Enrollment , history nongonococcal urethritis and/or sexually transmit infection ( STI ) , include outbreak genital herpes condylomata For uncircumcised men , treatment candidal balanoposthitis/ balanitis within 30 day prior Enrollment History recurrent dermatosis ( e.g . eczema ) Nontherapeutic injection drug use 12 month prior Screening Currently use immunosuppressant ( exception local nongenital use low potency product e.g . inhale corticosteroid asthma ) Has follow laboratory abnormality Screening : Hemoglobin &lt; 10.0 g/dL Platelet count &lt; 100,000/mm3 White blood cell count &lt; 2,000 cells/mm3 Alanine transaminase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5x site laboratory upper limit normal ( ULN ) Serum creatinine &gt; 1.3x site laboratory ULN Calculated creatinine clearance le 80 mL/min CockcroftGault formula creatinine clearance mL/min = ( 140age year ) x ( weight kg ) x 0.85/72 x serum creatinine mg/dL Note : Otherwise eligible participant exclusionary laboratory result may retested . If participant retested non exclusionary result document within 30 day provide informed consent Screening , participant may enrol . At Screening Enrollment , diagnose STI reproductive tract infection ( RTI ) require treatment , per current Centers Disease Control Prevention ( CDC ) guideline At Screening Enrollment , clinically apparent Grade 1 high genital exam finding ( observe study staff ) At Screening Enrollment , Grade 1 high genital urinary symptom At Screening Enrollment , diagnose phimosis hypospadias At Screening Enrollment , penile , scrotal pierce penile tattoo observe genital examination Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>male tolerance</keyword>
	<keyword>HIV-1</keyword>
	<keyword>microbicide</keyword>
	<keyword>The study assess safety tolerability dapivirine apply topically penis healthy , HIV-uninfected , adult male , circumcise</keyword>
	<keyword>uncircumcised</keyword>
</DOC>